Literature DB >> 26376026

The hypotensive effect of the nitric monoxide donor Oxacom at different routs of its administration to experimental animals.

Alexander А Тimoshin1, Vladimir L Lakomkin1, Alexander А Аbramov1, Enno K Ruuge1, Valery I Kapel'ko1, Evgeny I Chazov1, Anatoly F Vanin2.   

Abstract

Earlier it has been found that the hypotensive drug Oxacom containing binuclear dinitrosyl iron complexes (B-DNIC) with glutathione can effectively decrease, as a nitric monooxide (NO) donor, the mean arterial pressure (МАР) in rats upon intravenous bolus injection in the form of an aqueous solution (Chazov et al., 2012). The aim of this study was to investigate the hypotensive effects of Oxacom administered to experimental rats by intravenous, intramuscular, subcutaneous, intraperitoneal, intragastric, rectal routes.MAP and heart rate (HR) were measured with the help of arterial catheters equipped with tensometric sensors. Oxacom was administered to rats at the dose of 2.0 μmole of B-DNIC/kg. The concentration of paramagnetic mononuclear protein-bound DNIC (М-DNIC) formed in the blood and tissues of various internal organs of the rat was determined by the EPR method. Upon subcutaneous, intramuscular or intraperitoneal administration of Oxacom, the maximum amplitude of the МАР decrease varies from 30% to 70%, respectively, in comparison with the corresponding parameter for the intravenously injected Oxacom. Another difference is the lack of the fast phase in the initial stage of the МАР decrease and the longer persistence of protein-bound M-DNIC formed in the circulating blood after intramuscular, subcutaneous or intraperitoneal administration of Oxacom. Thus, the NO donor Oxacom exerts pronounced hypotensive effects on rats not only upon intravenous, but also upon intramuscular, subcutaneous or intraperitoneal administration.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dinitrosyl iron complexes; Hypotension; Oxacom

Mesh:

Substances:

Year:  2015        PMID: 26376026     DOI: 10.1016/j.ejphar.2015.09.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.

Authors:  A F Vanin; A V Pekshev; A B Vagapov; N A Sharapov; V L Lakomkin; A A Abramov; A A Timoshin; V I Kapelko
Journal:  Biophysics (Oxf)       Date:  2021-04-27

2.  Detection of dinitrosyl iron complexes by ozone-based chemiluminescence.

Authors:  George T Mukosera; Taiming Liu; Abu Shufian Ishtiaq Ahmed; Qian Li; Matilda H-C Sheng; Trent E Tipple; David J Baylink; Gordon G Power; Arlin B Blood
Journal:  Nitric Oxide       Date:  2018-07-27       Impact factor: 4.427

3.  Hemodynamic Effects of Glutathione-Liganded Binuclear Dinitrosyl Iron Complex: Evidence for Nitroxyl Generation and Modulation by Plasma Albumin.

Authors:  Taiming Liu; Meijuan Zhang; Michael H Terry; Hobe Schroeder; Sean M Wilson; Gordon G Power; Qian Li; Trent E Tipple; Dan Borchardt; Arlin B Blood
Journal:  Mol Pharmacol       Date:  2018-02-23       Impact factor: 4.436

4.  Protective Effects of Dinitrosyl Iron Complexes under Oxidative Stress in the Heart.

Authors:  Valery I Kapelko; Vladimir L Lakomkin; Alexander A Abramov; Elena V Lukoshkova; Nidas A Undrovinas; Asker Y Khapchaev; Vladimir P Shirinsky
Journal:  Oxid Med Cell Longev       Date:  2017-03-21       Impact factor: 6.543

5.  Spray with Nitric Oxide Donor Accelerates Wound Healing: Potential Off-the-Shelf Solution for Therapy?

Authors:  Alexandra Igrunkova; Alexey Fayzullin; Semyon Churbanov; Polina Shevchenko; Natalia Serejnikova; Natalia Chepelova; Dmitry Pahomov; Ekaterina Blinova; Karen Mikaelyan; Victoria Zaborova; Konstantin Gurevich; Aleksandr Urakov; Anatoly Vanin; Peter Timashev; Anatoly Shekhter
Journal:  Drug Des Devel Ther       Date:  2022-02-16       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.